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Abstract
Family practitioners play an important role in educating patients about the prevention of malaria. Many patients still believe that 
malaria prophylaxis is negotiable and it is the family practitioner’s duty to fully inform patients about the deadly complications 
of malaria and the rationale behind chemoprophylaxis. This article is patient orientated and will provide the family practitioner 
with useful information for this important task.  
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Introduction
Malaria is a serious parasitic disease 
that occurs when an infected Anophe-
les mosquito bites a person and injects 
malaria parasites into the blood. Four 
species of malaria parasites can infect 
humans and cause illness; only P. falci-
parum malaria is potentially life-threat-
ening. Most of the malaria found in Af-
rica is of the falciparum species - this is 
the most dangerous species of malaria. 
Symptoms may develop as soon as 
seven days after arrival in a malarious 
area, or in the case of vivax and ovale 
malaria, as long as eighteen months af-
ter leaving a malarious area. Symptoms 
of malaria are often beguilingly mild in 
the initial stages, resembling influenza. 
Symptoms of malaria may include 
a generalised body ache, tiredness, 
headache, sore throat, diarrhoea, and 
fever. It is worth emphasising that these 
initial symptoms may not be dramatic, 
and can easily be mistaken for an 
attack of influenza or similar non-life 
threatening illness. Deterioration can 
then be sudden and dramatic - a high 
swinging fever may develop, with 
marked shivering and dramatic per-
spiration. Complications of a serious 
nature and death due to the inherent 
microvascular nature of the disease 
may then follow. 
 
Factors that encourage the propaga-
tion of malaria include:
§  High Anopheles mosquito popula-
tions after wet, warm periods
§  High density of infected people in 
the area and
§  High minimum night time tempera-
tures, encouraging the develop-
mental phase of the malaria parasite 
inside the mosquito
Prevention relies upon three things: 
personal protection measures, anti-
malaria tablets, and getting the right 
information. Mosquito bites can be 
reduced by applying insect repellent 
to exposed skin. Recommended re-
pellents contain 20%-35% DEET, and 
there are a number of brands on the 
market. Long-sleeved clothing and 
long pants should be worn if outdoors 
at night. Mosquito nets should be used 
if the traveller’s bedroom is not air-con-
ditioned and sealed. Spray insecticide 
or burn a coil in the bedroom or tent 
before going to bed. Vitamin B and 
ultrasound buzzer devices are quite 
useless at preventing mosquito bites. 
Malaria chemoprophylaxis is recom-
mended to all travellers to malarious 
areas; local residents who have been 
raised in the area should not use medi-
cation. One commonly held and po-
tentially fatal belief is that anti-malaria 
pills are best avoided, as they merely 
mask the disease and make diagnosis 
difficult. Should malaria then develop, 
it is allegedly an easy matter to take a 
handful of tablets to cure it. 
The critical aspect of malaria preven-
tion is getting the right information. Ac-
curate information about the traveller’s 
destination’s malaria risk is vital, as is 
the advice regarding appropriateness 
of recommended medication for the 
traveller as an individual.
Travellers journeying to remote ar-
eas, and people living in distant areas 
should consider carrying a malaria 
standby diagnosis and treatment pack, 
to allow prompt and accurate treatment 
of malaria in areas out of reach of medi-
cal care.
High risk travellers
Pregnant women and young children 
under 5 years are at increased risk of 
severe complication, and should not 
travel into malarial areas. In addition to 
the risk of complication, children and 
pregnant women are more likely to con-
tract malaria as they are more attractive 
to mosquitoes. Splenectomised travel-
lers are more at risk of rapidly progres-
sive malaria.
1.  Remember - cure is not always 
possible, so it’s worth preventing 
malaria at all costs.
2.  Even if the malaria tablets only 
suppress the parasite partially, 
they will still save your life. 
3.  The seriousness of malaria war-
rants tolerating temporary and 
mild side effects.
4.  Travellers are warned of the risk 
of abandoning prophylaxis on the 
basis of hear-say from quasi- or 
pseudo-experts, leaving them-
selves at risk of malaria in remote 
areas with poor medical facilities. 
Box 1: Four aphorisms for travellers
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Malaria and the HIV infected, non-im-
mune traveller
A definitive study to assess the effect of 
HIV-infection, advancing immuno-sup-
pression and pre-existing anti-malarial 
immunity on the severity of malaria 
has confirmed that HIV-infected non-
immune adults (i.e. individuals whose 
childhood years were spent in areas 
where malaria does not occur) are at 
increased risk of severe malaria - and 
that their risk is even greater if their 
CD4+ T cell count is low. 
The study was conducted on 336 
patients hospitalised with falciparum 
malaria in South Africa, 10% of whom 
had severe malaria, and involved tests 
for HIV antibodies, CD4+ T cell count 
and assessment for the clinical fea-
tures of severe malaria. The prevalence 
of HIV infection in the study population 
was 33%, and 33% of the patients were 
non-immune to malaria.  
An analysis of the test criteria found 
that the main risk factors for severe 
malaria were non-immunity to malaria, 
a positive HIV serostatus, an elevated 
parasite count and having an increased 
white blood cell count. Moreover, the 
risk of severe malaria was increased 
in HIV-infected patients with a reduced 
CD4+ count. Non-immune HIV-infected 
patients were significantly more likely 
to have severe malaria (36%) than were 





•  Avoid sleeping near mosquito har-
boring areas – swamplands, marsh-
es and areas of thick vegetation 
•  Avoid alcohol in such excess that 
awareness of risk situations is dimin-
ished i.e. falling asleep in the open. 
This is particularly important in warm 
areas.
•  Recreational activity must be 
planned to accommodate the pos-
sibility of exposure to mosquitoes 
eg night time barbecues in the open 
should be avoided  
b Clothing 
•  Wear garments that fully cover arms 
and legs when outdoors between 
sunset and sunrise 
•  Light cotton jackets, slacks and hats 
to be worn
c. Accommodation
•  Impregnated mosquito nets should 
be used to sleep under
•  Accommodation should be mosqui-
to proofed with mesh and residual 
indoor spraying
d. Insect repellants
•  Only DEET based agents must be 
supplied and used in the form of 
lotions, sticks and sprays. Citronella 
based repellants are essentially inef-
fective
•  Travellers should apply these liber-
ally on all exposed skin surfaces 
after sunset
e.  Combustible mosquito coils or 
electrically heated mat units 
should be used if feasible
f.  Where feasible air conditioning 
units or electric fans (in addition 
to the above) may be utilised  
CPD Article
Box 2: What is personal protection exactly?
•  Cover up - long sleeves and trou-
sers at night
•  Avoid night time braais and par-
ties outdoors.
•  DEET repellents eg Tabard are 
the most effective
• Citronella is poorly effective
• Treated bed nets should be used
• Sonic buzzers are useless
Oral Prophylactic Agents
Only three agents are advocated by 
South Africa for Sub-Saharan Africa ac-
cording to efficacy and safety, namely:
1. Doxycycline (For example, Doxitab®)
• 1 tablet per day after meals 
•  Starting 48 hours prior to entering 
a malaria area and continuing for 4 
weeks after exiting the area
 
2. Mefloquine  (Lariam®, Mefliam®)
• 1 tablet per week after meals
•  Starting 10 days to 2 weeks prior to 
entering a malaria area – to ensure 
adequate and stable blood levels 
- and continuing for 4 weeks after 
exiting the area.
•  Not recommended for divers, pilots, 
climbers and anyone at risk of de-
pression
3. Atoraquine + proguanil (Malanil®)
• 1 tablet per day 
•  Starting 24 hours prior to departure 
and for 7 days after exiting the area
•  Convenient for short term visits to 
malaria areas but expensive for the 
long term
Travellers should be reminded that 
all of these agents are only effective 
if used according to the prescribed 
method, and that haphazard use ren-
ders them totally ineffective. 
Box 2: Can malaria prophylaxis be used 
safely for long periods?
•  Once a client is compliant on one 
prophylactic regimen and is toler-
ating it well, transfer to another 
regimen increases the likelihood 
of the development of side effects 
due to the introduction of a diffe-
rent drug.
•  There is no evidence of new side 
effects from long-term use of any 
currently available prophylactics 
(except from the exceedingly 
long-term use of chloroquine (not 
used in Africa now), and very 
rarely).
•  Evidence for safety in long-term 
use comes from an accumulating 
lack of evidence of harm 
•  In areas where malaria transmis-
sion is high the risk of disease 
greatly exceeds the risk of ad-
verse drug effects.
•  Individual risk assessments are 
important when deciding what ad-
vice should be given. In particular 
the other measures that will be 
used by those staying long-term 
in an area where the risk varies 
with the season may influence 
the advice.
•  Simplicity in regimen can, as 
always, be expected to improve 
compliance. The safest option is 
compliance with one of the most 
effective regimens.
•  Minimising exposure to infection 
is important, especially protection 
from being bitten whilst asleep.
•  It is essential to seek medical 
advice promptly if symptoms de-
velop. 
Extract from: Malaria prophylaxis for 
long-term travelers. Commun Dis Pub-
lic Health 2003; 6(3): 200-8
Side effects of antimalarial chemo-
prophylaxis drugs
If a serious side effect occurs, the trav-
eller should seek medical help and dis-
continue taking the antimalarial drug. 
Mild nausea, occasional vomiting, or 
loose stools are not adequate reasons 
for stopping the antimalarial drug. 
Table 1 summarises the side effects 
and contraindications of the antimalari-
als.
Management of possible and proven 
malaria cases
Despite compliant chemoprophylaxis 
there is still the possibility of the trav-
eller developing malaria. The essence 
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Name of antimalarial Advantages Disadvantages
Mefloquine – (Lariam® and Mefliam®)
Once a week dosage
Effective
Inexpensive
Safe in 2nd and 3rd trimester 
Side effects in some people (<20% mild, <2% severe)
Take for 4 weeks after return
Not ideal for machine operators, drivers or those that work 
at heights (although the US and Israeli Air forces use it)
Not for use in people with a history of
• Epilepsy
• Depression
• Other psychiatric problems
• Arrhythmias  requiring treatment
Patients taking beta blockers, calcium channel blockers 




Old drug – no surprises
Inexpensive 
Antibiotic – prevents other diseases 
such as tick bite fever





Can cause increased sunburn susceptibility
Can cause thrush in women
Take for 4 weeks after return 
Cannot be used in children
Cannot be used during pregnancy 
Drug interactions with oral contraceptives
Atovaquone plus proguanil (Malanil®)
Effective 
Very well tolerated
Take only for 7 days after return




Can be used long term, although costly 
Not for use in pregnancy
Newer drug
Table 1: Antimalaria drugs
of successful malaria management 
is early treatment. To achieve this re-
quires awareness in the traveller of the 
symptoms and the importance of being 
tested without delay.
Possible malaria
Any traveller who feels unwell should 
be urgently tested for malaria. Any or 
all of the following symptoms should 
be explained to the traveller and must 











• Tiredness / fatigue
• Hot and cold shivers
Box 4 summarises the initial manage-
ment of suspected malaria cases.
Testing for malaria away from home:
It must be pointed out to the traveller 
that no symptom or physical sign is 
specific for malaria i.e. they can be 
present in any number of infectious 
diseases from common flu to more seri-
ous illness. The only certain method of 
diagnosis is to perform tests that are 
specific for malaria. There are basically 
two tests available in most malarious 
areas:
a. Rapid tests
These are sensitive and reliable enough 
to be used by anybody with minimal 
training. No specialised equipment or 
laboratory facilities are required. They 
are also portable and temperature 
stable enough to be transported and 
stored in temperatures up to 300 C 
without special facilities. The ICT card 
test for falciparum, specifically, is rec-
ommended.   
b. Blood slides  (done in laboratory)
Blood smears are the gold standard of 
malaria tests for the following reasons: 
1.  Any traveller who complains of symptoms should lie down in a protected, cool area.
2.  Treat symptoms with paracetemol (Panado®) 2 tablets every 4 hours (max 8 /day). Avoid 
non-steroidal anti- inflammatories – as these can lead to renal failure.
3.  A rapid malaria test must be performed without delay
4.  If possible blood smears should be performed if a reliable laboratory is available.
IF MALARIA IS DIAGNOSED OR SUSPECTED
Estimate the severity of the symptoms by ticking the following check list
  Impaired consciousness- drowsy to coma
  Jaundice (yellow eyes)
  Vomiting
  Cold clammy and weak (usually implies low blood pressure)
  Temp >39ºC
  Low blood sugar (<2.5mmol/l on meter)
 Cough 
 Pallor
  Dehydration – sunken eyes, loss of skin elasticity
  No or little urine production (<400ml in 24 hours)
 Pregnancy 
 Under 5 yrs
  High level of parasites in blood (>3%) diagnosed on a slide
If any of the above signs are present, this is an emergency.
This signifies complicated malaria and the patient must be evacuated to expert medical care 
immediately.
•  False positives or negative results 
are uncommon in good hands, BUT 
inaccurate results are common in 
African state  and private clinics (up 
to 50% wrong results in West Africa)
•  The species of malaria can be iden-
tified
•  The severity of the parasitaemia can 
be determined which is paramount 
in decision making regarding the 
treatment and management of the 
patient
•  Progress and effectiveness of treat-
ment can be monitored 
Box 4: Rules for possible or confirmed malaria cases away from home
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Treatment options 
The following drugs can be taken for 
the treatment of uncomplicated or 
interim management of complicated 
malaria. 
•  Co-artemether (Coartem®)
  Adults – 4 tablets immediately, then 
4 tablets after 8 hours. Then 4 tab-
lets 12 hourly for 4 doses. Take pills 
with food that contains oil e.g. chips, 
bread and butter.
OR (if Coartem® is not available, or in 
the unlikely event of failed treatment)
• Quinine & Doxycycline
Adults – Quinine 600 mg (2 tablets) 
three times daily for 7-10 days after 
food, adding doxycycline 100 mg 
twice daily for 7-10 days or clindamycin 
10mg/kg for seven days (young chil-
dren and pregnant women) on day 3. 
• Be tough - don’t cover up
• Take the pills irregularly or not at all
•  Stop the pills as soon as you get 
back
• If you do take pills - use a friend’s
• Ignore flu like symptoms
•  Take advice from locals and other 
experts - hairdressers and fishing 
buddies
Box 5: How to die of malaria
Conclusion
Advising patients on malaria prophy-
laxis should always be on top of the 
practitioner’s mind and should not 
be offered only to those who ask for 
advice. Asking patients about their holi-
day plans is a very natural and, in fact, 
essential way to start a consultation 
and provides a golden opportunity to 
advocate safe practices about malaria 
prevention. 
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Announcement
Dear Academy members and colleagues,
Notice of the first Board elections for the “New Academy” together with nomination papers will be reaching you through the post, 
soon.  Please make a note of the following dates:
Final date for lodging of nominations: 02 December 2006
Last date to receive returned voting papers: 19th January 2007
Date of Election:    25th January 2007
Date of Annual General Meeting  06th February 2007
Please ensure that your nomination forms are lodged in good time.  Bear in mind that the composition of the Board should be in 
line with the country’s equity rules in terms of representivity.
Shadrick Mazaza
National Chairman:  The SA Academy of Family Practice/Primary Care 
ELECTION OF THE ACADEMY’S BOARD OF DIRECTORS
